Table 2.
Reporting of equity considerations in health-equity-relevant randomized trials
| Cluster RCTs N = 100 |
Individual RCTs N = 100 |
Total N = 200 |
|
|---|---|---|---|
| (%) | (%) | N (%) | |
| Studies with any subgroup analysis across PROGRESS characteristics | 25 | 49 | 74 (37) |
| Primary reported subgroup analysis across PROGRESS characteristics: | |||
| Place of residence | 3 | 2 | 5 (3) |
| Race/ethnicity/culture | 5 | 13 | 18 (9) |
| Occupation | 0 | 1 | 1 (0.5) |
| Gender/sex | 13 | 24 | 37 (19) |
| Education | 1 | 3 | 4 (2) |
| Socioeconomic status | 3 | 5 | 8 (4) |
| Social capital | 0 | 1 | 1 (0.5) |
| PROGRESS characteristics adjusted for in analysis: | |||
| Place of residence | 7 | 3 | 10 (5) |
| Race/ethnicity/culture | 11 | 18 | 29 (15) |
| Occupation | 1 | 5 | 6 (3) |
| Gender/sex | 17 | 29 | 46 (23) |
| Religion | 1 | 2 | 3 (2) |
| Education | 14 | 15 | 29 (15) |
| Socioeconomic status | 11 | 14 | 25 (13) |
| Social capital | 0 | 2 | 2 (1) |
| Applicability/generalizability/external validity discussed across any PROGRESS characteristic | 68 | 73 | 141 (71) |
| Studies that had conducted a subgroup analysis and discussed equity with regards to the applicability of the evidence | 18 | 33 | 51 (26) |